Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy
Abu-Sbeih H, Tang T, Ali F, Luo W, Neelapu S, Westin J, Okhuysen P, Foo W, Curry J, Richards D, Ge P, Wang Y. Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. American Journal Of Clinical Oncology 2019, 42: 789-796. PMID: 31478934, DOI: 10.1097/coc.0000000000000596.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge DistributionAntineoplastic Combined Chemotherapy ProtocolsAsparaginaseBiopsy, NeedleCohort StudiesCytarabineDaunorubicinFemaleGastric MucosaGastritisGastrointestinal DiseasesHematologic NeoplasmsHumansImmunohistochemistryImmunotherapy, AdoptiveIncidenceMaleMiddle AgedPrognosisReceptors, Chimeric AntigenRetrospective StudiesRisk AssessmentSeverity of Illness IndexSex DistributionThioguanineConceptsChimeric antigen receptor T-cell therapyCytokine release syndromeGastrointestinal adverse eventsGI AEsT-cell therapyRefractory colitisEncephalopathy syndromeRelease syndromeAdverse eventsHematologic malignanciesDiffuse large B-cell lymphomaLarge B-cell lymphomaGastrointestinal tract inflammationGrade 1 diarrheaOnly symptomatic treatmentStandard of careCertain hematologic malignanciesB-cell lymphomaCART infusionAbdominal distensionAbdominal painBloody stoolGastrointestinal symptomsMedian durationExperienced diarrheaAcute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab
Zhang H, Luo W, Wang Y. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab. Journal For ImmunoTherapy Of Cancer 2019, 7: 47. PMID: 30777137, PMCID: PMC6380028, DOI: 10.1186/s40425-019-0532-1.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsAntirheumatic AgentsChemical and Drug Induced Liver InjuryColitisColonDiarrheaHumansInfliximabIpilimumabLiverMaleNivolumabProstatic NeoplasmsConceptsImmune-related adverse reactionsGrade 3 colitisGastrointestinal reactionsLiver injuryClinical historyImmune checkpoint inhibitor-related colitisBackgroundImmune checkpoint inhibitorsElevated liver enzymesPD-1 inhibitorsTNF-α agentsAcute liver injuryInflammatory bowel diseaseOne-time infusionInfliximab therapyAcute hepatitisCheckpoint inhibitorsRescue therapyAdvanced malignanciesBiologic agentsBowel diseaseLiver profileCase presentationWePatient populationCTLA-4Final diagnosis